Table 1.

Patient characteristics at baseline

CharacteristicResults (N = 40)
Mean age, y (range)54.8 (30–79)
Sex (male/female), n (%)18/22 (45.0/55.0)
Race, n (%)
    Asian1 (2.5)
    Black or African American4 (10.0)
    White35 (87.5)
Mean years since diagnosis (SD)3.3 (4.62)
Mean years since metastasis (SD)2.6 (4.57)
Prior antitumor therapy, n (%)
    Prior chemotherapy or radiotherapy36 (90.0)
    Prior chemotherapy and radiotherapy12 (30.0)
Median prior chemotherapy regimens, n (range)3.0 (0–7)
Tumor type, n (%)
    Colorectal cancer14 (35.0)
    Papillary renal carcinoma4 (10.0)
    Ovarian adenocarcinoma5 (12.5)
    Renal cell carcinoma3 (7.5)
    Melanoma3 (7.5)
    Thyroid cancer3 (7.5)
    Sarcoma2 (5.0)
    Neuroendocrine metastatic
        Pancreatic1 (2.5)
        Pulmonary carcinoid (atypical)1 (2.5)
    Adenocarcinoma, clear cell (urethral)1 (2.5)
    Breast carcinoma (invasive ductal)1 (2.5)
    Squamous cell carcinoma (anorectal)1 (2.5)
    Hepatocellular1 (2.5)